Johnson & Johnson confirms opioid business has ended in $230 million settlement with New York

Business

New York State Attorney General, Letitia James, speaks during a news conference, to announce criminal justice reform in New York City, U.S., May 21, 2021.
Brendan McDermid | Reuters

New York Attorney General Letitia James announced on Saturday that Johnson & Johnson has agreed to halt sales of opioids nationwide in a $230 million settlement with New York state.

As part of the settlement, the company will resolve opioids-related claims and allocate payments over nine years. It could also pay $30 million more in the first year if the state executive chamber signs into law new legislation creating an opioid settlement fund, according to the press release from James’ office.

“The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids,” James said in a statement.

“Johnson & Johnson helped fuel this fire, but today they’re committing to leaving the opioid business — not only in New York, but across the entire country,” she said.

This is breaking news. Please check back for updates.

Articles You May Like

Pinterest shares soar 18% on earnings beat, strong revenue growth
Digital Taxation around the World
FTC challenges ‘junk’ patents held by 10 drugmakers, including for Novo Nordisk’s Ozempic
Bitcoin just completed its fourth-ever ‘halving,’ here’s what investors need to watch now
Walmart launches new grocery brand, as it tries to hang on to inflation-fueled growth